LAAx said its TigerPaw System II is indicated for occlusion of the left atrial appendage (LAA) under direct visualization, in conjunction with other open cardiac procedures.
LAAx president and CEO Bill Wheeler said they will work together to get the TigerPaw System II into the hands of cardiac surgeons who have not yet had access to a clinically proven, 100% occlusive LAA closure device.
"This clinical outcome expectation will benefit patients who need to reduce the medical risks associated with a less than 100% closure of the LAA," Wheeler said.
